Emergent BioSolutions (EBS) Retained Earnings (2010 - 2026)

Emergent BioSolutions' Retained Earnings history runs 17 years deep, the most recent figure standing at -$153.0 million for Q1 2026.

• On a quarterly basis, Retained Earnings fell 2408.2% year-over-year to -$153.0 million in Q1 2026; TTM through Mar 2026 was -$153.0 million, a 2408.2% decrease from a year earlier, with the FY2025 full-year figure at -$7.5 million, up 96.47% from the prior year.
• Retained Earnings eased to -$153.0 million in Q1 2026 per EBS's latest filing, from -$7.5 million in the prior quarter.
• Across five years, Retained Earnings topped out at $924.4 million in Q3 2024 and bottomed at -$212.4 million in Q4 2024.
• The 5-year median for Retained Earnings is -$5.5 million (2024), against an average of $286.3 million.
• Across the five-year window, Retained Earnings surged 35653.85% in 2024 and plunged 2408.2% in 2026, its largest moves.
• Year by year, Retained Earnings stood at $738.7 million in 2022, then gained by 22.43% to $904.4 million in 2023, then tumbled by 123.49% to -$212.4 million in 2024, then jumped by 96.47% to -$7.5 million in 2025, then plunged by 1940.0% to -$153.0 million in 2026.
• Per Business Quant, the three latest EBS Retained Earnings figures stand at -$153.0 million (Q1 2026), -$7.5 million (Q4 2025), and -$105.2 million (Q3 2025).